Speaker Biography


Amit B Aiwale has expertise in both Cranial and spine surgeries, has done DNB neurosurgery from CARE Hospital Hyderabad and completed Fellowship in Neuro-endoscopy under Prof. Dr. Y. R. Yadav and WFNS Fellowship under Dr. Basant K. Misra. He has done many podium paper and poster presentations in many Indian National and state level conferences. He has won many Neurosurgical Quiz as resident during training period. At very young age with interest in research work during the training period he received the Next Gen Young Neurosurgeon award in 2018 along with Abstract publication in International Neurosurgery Update 2018 held at Mumbai India. Now he is Associated with one of renowned institutes in India P.D. Hinduja National Hospital and research Centre Mahim, Mumbai


The current diagnostic techniques are relatively insensitive in diagnosing and grading CNS tumors, resulting in a delay in diagnosis until disease progressed or recurrence related symptoms are profound and irreversible and therapeutic options are limited or non-existent. miRNA can be useful as biomarkers for cancer detection because:(i) miRNA expression is frequently dysregulated in cancer (ii) expression patterns of miRNAs in human cancer appear to be tissue-specific and (iii) miRNAs have unusually high stability in formalin-fixed tissues. In our institute when we studied CNS tumors patients with miRNA 7,21,33,34 and 200 expressions in tumor tissue, CSF and serum we found the expression levels of miRNA 7,21,33,34 and 200 was significantly high in tissue samples in both males and females whereas no significant difference was observed gender wise in any type of sample analyzed. The expression levels of miRNA-7,34 and 200 being tumor suppressor related miRNA were found in high folds in grade1 tumors compared to high grade tumors. While the miRNA21 found in higher folds in grade4 compared to grade1 glioma. Consistent downregulation was observed for the expression of miRNA-33 in tissue and CSF samples from grade1 to grade4 CNS tumors. However, no significant variation was observed in serum. The graphical pattern of presentation of miRNA7,21,33,34 and 200 was typical in specific grade of gliomas i.e. grade1 to grade4. The fold change of presentation of miRNA may be variable but the graphical pattern remains relatively consistent in tumour tissue, CSF or blood samples from the patients with CNS tumours. We concluded that the miRNA analysis can become a future additional tool for diagnosis and follow up monitoring of patients with CNS tumors. miRNA in blood or CSF has specific graphical pattern in each individual grade of glioma and hence can be used as specific signature in prediction of conversion of low-grade glioma into high grade gliomas. Further research needs to be done with regards to role of other miRNA and the signature patterns